Abstract
Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Amifostine / administration & dosage
-
Amifostine / adverse effects*
-
Amifostine / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma / drug therapy*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects*
-
Cisplatin / therapeutic use
-
Drug Administration Schedule
-
Fatal Outcome
-
Female
-
Hearing / drug effects*
-
Humans
-
Injections, Intravenous
-
Kidney / drug effects*
-
Nervous System / drug effects*
-
Ovarian Neoplasms / drug therapy*
-
Recurrence
-
Treatment Outcome